Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones
Company to leverage positive Phase IIa pancreatic cancer results presented at ESMO 2026, two pivotal Phase III programs, and expanding patent protection to advance global partnering opportunities
Covered in this story
Call it yourself
No calls on $BIO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Bio-Rad Laboratories →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.